Search

Bruce A Sullenger

from Chapel Hill, NC
Age ~59
Get Report
Also known as:
Bruce Alan Sullenger, Sullenger Sullenger, Adim Abdisalam
Phone and address:
120 Serrano Way, Chapel Hill, NC 27514
(919) 932-1086
Related to:
Michelle C Engel, 46Anthony C Levine, 39John M Engel, 44Arthur SullengerRebecca Sullenger, 26Rita Semelsberger, 76
Connected to:
Barry W Sullender, 62Christopher Sullenger, 35Georgina M Sullender, 69Jean S Sullenger, 82Sherri Sullenger, 56Sue R Sullenger, 82Alec M Sullens, 29Jillian F Sullens, 38Kevin P Sullens, 39Kirk P Sullens, 64

Bruce Sullenger Phones & Addresses

  • 120 Serrano Way, Chapel Hill, NC 27514 (919) 932-1086
  • Dayton, OH
  • 11 Saint Andrews Ct, Durham, NC 27707 (919) 490-7900
  • Westminster, CO

Publications

Us Patents

Alteration Of Sequence Of A Target Molecule

View page
US Patent:
6897016, May 24, 2005
Filed:
Oct 2, 1998
Appl. No.:
09/165514
Inventors:
Bruce A. Sullenger - Westminster CO, US
Thomas R. Cech - Boulder CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
International Classification:
C12Q001/68
C12P019/34
C07H021/02
US Classification:
435 6, 435 5, 435 911, 435 912, 536 231, 536 245, 514 44
Abstract:
Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.

Alteration Of Sequence Of A Target Molecule

View page
US Patent:
7045293, May 16, 2006
Filed:
Mar 12, 2004
Appl. No.:
10/799535
Inventors:
Bruce Sullenger - Westminster CO, US
Thomas R. Cech - Boulder CO, US
Assignee:
The Regents of the University of Colorado - Boulder CO
International Classification:
C12Q 1/68
C12P 19/34
C07H 21/02
US Classification:
435 6, 435 5, 435 911, 514 44, 536 231, 536 241, 536 245, 536 251
Abstract:
Method for splicing a target nucleic acid molecule with a separate nucleic acid molecule. Such splicing generally causes production of a chimeric protein with advantageous features over that protein naturally produced from the target nucleic acid prior to splicing. The method includes contacting the target nucleic acid molecule with a catalytic nucleic acid molecule including the separate nucleic acid molecule. Such contacting is performed under conditions in which at least a portion of the separate nucleic acid molecule is spliced with at least a portion of the target nucleic acid molecule to form a chimeric nucleic acid molecule. In this method, the catalytic nucleic molecule is chosen so that it is not naturally associated with the separate nucleic acid molecule.

Modulators Of Pharmacological Agents

View page
US Patent:
7300922, Nov 27, 2007
Filed:
May 28, 2002
Appl. No.:
10/155233
Inventors:
Bruce A. Sullenger - Durham NC, US
Christopher P Rusconi - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 31/70
C07H 21/04
C12N 15/00
A61K 35/14
US Classification:
514 44, 536 231, 536 245, 435 6, 4353201, 530381, 530383, 530384
Abstract:
The biological activity of nucleic acid ligand is regulated (i. e. enhanced or inhibited) in vivo to produce a desired biological effect. This is accomplished through the administration of a modulator, or regulator, that changes the binding of the nucleic acid ligand for its target or that degrades or otherwise cleaves, metabolizes or breaks down the nucleic acid ligand while the ligand is still exerting its effect. Modulators of the present invention can be administered in real time as needed based on various factors, including the progress of the patient, as well as the physician's discretion in how to achieve optimal therapy. Thus, this invention provides for the first time a regulatable therapeutic regime in the course of nucleic acid ligand therapy.

Rna Aptamers And Methods For Identifying The Same

View page
US Patent:
7312325, Dec 25, 2007
Filed:
Sep 26, 2001
Appl. No.:
09/963827
Inventors:
Bruce A. Sullenger - Durham NC, US
Christopher P. Rusconi - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 31/70
C07H 21/02
C12N 5/00
C12Q 1/68
US Classification:
536 245, 536 231, 536 241, 435 6, 514 44
Abstract:
RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.

Rna Aptamers And Methods For Identifying The Same

View page
US Patent:
7741307, Jun 22, 2010
Filed:
Oct 26, 2007
Appl. No.:
11/925645
Inventors:
Bruce A. Sullenger - Durham NC, US
Christopher P. Rusconi - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 31/70
C07H 21/02
C07H 21/04
C12Q 1/68
C12N 5/00
US Classification:
514 44, 435 6, 536 231, 536 241, 536 245
Abstract:
RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.

Rna Aptamers And Methods For Identifying The Same

View page
US Patent:
7776836, Aug 17, 2010
Filed:
Oct 26, 2007
Appl. No.:
11/925648
Inventors:
Bruce A. Sullenger - Durham NC, US
Christopher P. Rusconi - Durham NC, US
Rebekah R. White - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
C07H 21/02
C07H 21/04
A61K 31/70
C12Q 1/68
US Classification:
514 44, 536 231, 536 241, 536 245, 435 6, 435455, 435375
Abstract:
RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.

Rna Aptamers And Methods For Identifying The Same

View page
US Patent:
7776837, Aug 17, 2010
Filed:
Nov 6, 2007
Appl. No.:
11/936015
Inventors:
Bruce A. Sullenger - Durham NC, US
Christopher P. Rusconi - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 31/70
C07H 21/02
C07H 21/04
C12Q 1/68
C12N 5/00
US Classification:
514 44, 536 231, 536 241, 536 254, 435 6, 435375
Abstract:
RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.

Rna Aptamers And Methods For Identifying The Same

View page
US Patent:
7812001, Oct 12, 2010
Filed:
Oct 26, 2007
Appl. No.:
11/925641
Inventors:
Bruce A. Sullenger - Durham NC, US
Christopher P. Rusconi - Durham NC, US
Assignee:
Duke University - Durham NC
International Classification:
A61K 31/70
C07H 21/02
C07H 21/04
C12Q 1/68
US Classification:
514 44A, 435 6, 435375, 536 231, 536 241, 536 245
Abstract:
RNA aptamers and methods for identifying the same are disclosed. The RNA aptamers selectively bind coagulation factors, E2F family members, Ang1 or Ang2, and therapeutic and other uses for the RNA aptamers are also disclosed.
Control profile
Bruce A Sullenger from Chapel Hill, NC, age ~59 Get Report